This week, the ratings of 14 Pharmaceuticals stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Allergan plc (AGN) gets weaker ratings this week as last week’s D drops to a F. Allergan plc is a healthcare company focused on developing and commercializing pharmaceuticals, biologics, and medical devices. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of AGN stock.

This is a rough week for Eli Lilly and Company (LLY). The company’s rating falls to D from the previous week’s C. Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. For more information, get Portfolio Grader’s complete analysis of LLY stock.

Pacira Pharmaceuticals, Inc. (PCRX) experiences a ratings drop this week, going from last week’s C to a D. Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company with focuses on the development, commercialization, and manufacturing of proprietary pharmaceutical products. The company also gets F’s in operating margin growth. For more information, get Portfolio Grader’s complete analysis of PCRX stock.

This week, Intersect ENT Inc (XENT) drops from a C to a D rating. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of XENT stock.

Revance Therapeutics, Inc.’s (RVNC) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of RVNC stock.

Intra-Cellular Therapies, Inc. (ITCI) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ITCI stock.

This week, Aradigm Corporation’s (ARDM) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARDM stock.

Slipping from a D to a F rating, Cumberland Pharmaceuticals Inc. (CPIX) takes a hit this week. Cumberland Pharmaceuticals Inc. engages in the acquisition, development, and commercialization of branded prescription products for the hospital acute care and gastroenterology markets primarily in the United States. The company also gets F’s in sales growth, operating margin growth, and earnings growth. For more information, get Portfolio Grader’s complete analysis of CPIX stock.

AcelRx Pharmaceuticals, Inc. (ACRX) is having a tough week. The company’s rating falls from a C to a D. AcelRx Pharmaceuticals, Inc. focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACRX stock.

Endocyte, Inc. (ECYT) declines this week from a D to a F. Endocyte, Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ECYT stock.

Alcobra Ltd. (ADHD) slips from a D to a F this week. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ADHD stock.

Dipexium Pharmaceuticals, Inc. (DPRX) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of DPRX stock.

This week, Alimera Sciences, Inc.’s (ALIM) rating worsens to a D from the company’s C rating a week ago. Alimera Sciences, Inc. engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of ALIM stock.

Slipping from a C to a D rating, Bio-Path Holdings, Inc. (BPTH) takes a hit this week. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of BPTH stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.